

ASX ANNOUNCEMENT

Chairman's Address at General Meeting

Sydney, 17 July 2013: The Chairman of Benitec Biopharma Ltd (ASX: BLT), Mr Peter Francis, today made the following address to the General Meeting of Benitec Biopharma Ltd shareholders.

"Recently I wrote to shareholders concerning the progress of our capital management program.

As previously announced on 6 June 2013, Benitec plans to raise up to A\$3,000,000 via a Share Purchase Plan (SPP).

Under the Share Purchase Plan, shareholders will be entitled to take up to A\$10,000 per holding on the same terms as the June 2013 Private Placement. Offer documents for the SPP were sent to shareholders on 24 June 2013. The record date for determining shareholders who are permitted to participate in the Share Purchase Plan is 31 May 2013 and I invite eligible shareholders to participate in the Benitec Share Purchase Plan.

In addition to the Share Purchase Plan, this General Meeting refers to recent successful capital management program activities

Most notably, we have received commitments for a private placement raising A\$7,000,000 subscribed to by new and existing institutional and sophisticated investors, announced on 6 June 2013. This was in addition to private placements totalling A\$980,000 announced in March 2013.

Furthermore, Benitec is seeking approval at this meeting to raise up to an additional A\$3,000,000 of over-subscriptions as part of the June 2013 private placement.

Approval is also being sought at this meeting for a proposed 25-for-1 consolidation of the Company's issued securities, as well approval of Director's participation in the previously announced March and June 2013 private placements.

Proceeds from the private placement and Share Purchase Plan will support the Company's Phase I/IIa hepatitis C clinical trial of TT-034, planned to commence in the US later this year.

In addition, the Company will complete preclinical toxicology, biodistribution and dose-finding studies for Tribetarna™, its drug resistant non-small cell lung cancer (NSCLC) program, and conduct a European based Phase I/IIa clinical trial in drug resistant NSCLC patients. The Company will also use the proceeds to manufacture clinical material for a potential second HCV clinical trial (based on outcomes from the first trial), in addition to advancing pre-clinical studies in other pipeline programs.

This is a very exciting time for Benitec as we are in transition from a preclinical to a clinical stage company. We anticipate that achieving clinical success will significantly enhance the value of the Company for its shareholders.

Thank you for your ongoing support of Benitec and we hope you will consider participating in the Share Purchase Plan."



For more information please contact: Dr Peter French | Chief Executive Officer
Phone: +61 (02) 9555 6986 | pfrench@benitec.com | www.benitec.com

About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.